Boyds Acquires New Cambridge Office to Support Rapid Growth
Boyds, the drug development consultancy which helps pharmaceutical companies translate great science into marketable medicines for patient benefit, has relocated into new premises in Cambridge.
The company has invested in excess of £0.5m in the purchase and complete refurbishment of a 1700 sq ft building located at South Cambridge Business Park in Sawston.
Boyds was previously located in Cottenham, a village on the outskirts of the city, and its head office will remain in Crewe, Cheshire.
Professor Alan Boyd, CEO and founder of Boyds said the team had outgrown its former property after a period of swift growth.
He said: “Our team has grown significantly in the last 12 months and we needed more space so we could futureproof our building for further new capacity in the months and years ahead.
“We remain in a prime location, close to academic groups, start-up hubs and industry, with several science parks within a five-mile radius.
“We also now have a dedicated meeting room facility that can support large client meetings and seminars.”
Professor Boyd said Boyds was committed to Cambridge as the city continues to be a thriving scientific hub that is recognised globally for its excellence in innovative research, and can be easily reached from London.
He added: “Cambridge is an ideal location for Boyds as it is optimally aligned with our goal to provide expert consultancy services for clients globally who are focusing on innovative products and treatment approaches.”
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018